NGAL (Neutrophil Gelatinase-Associated Lipocalin) as an early biomarker of nephropathy in patients with type 2 diabetes

Magdy Helmy Zikry Megallaa; Mohamed Said Abdel Salam; Neveen Lewis Mikhael Saad; Mohamed Nagy Abdel Hay Ahmed Altair; Noha Gaber Amin

doi:10.1080/20905068.2023.2230051

10.1080/20905068.2023.2230051 386 المشاهدات 3 الاقتباسات

الاقتباسات

386

المشاهدات

الملخص غير متوفر لهذا المنشور.

الاستشهاد بهذا المقال (APA)

Magdy, H. Z. M., Mohamed, S. A. S., Neveen, L. M. S., Mohamed, N. A. H. A. A., Noha, G. A. (2023). NGAL (Neutrophil Gelatinase-Associated Lipocalin) as an early biomarker of nephropathy in patients with type 2 diabetes. Alexandria Journal of Medicine. https://doi.org/10.1080/20905068.2023.2230051

Mohd. Javaid; Abid Haleem · 2018

309

استشهاد

390

A review of phage mediated antibacterial applications

Kenneth Ssekatawa; Denis K. Byarugaba; Charles D. Kato; Eddie M. Wampande; Franc · 2020

استشهاد

387

Antimicrobial resistance pattern and molecular epidemiology of ESBL and MBL producing <i>Acinetobact…

Rehab M. Abd El-Baky; Sara M. Farhan; Reham A. Ibrahim; Khaled M. Mahran; Helal · 2020

استشهاد

390